血必净注射液对脓毒症患者细胞免疫的影响

目的探讨血必净注射液对脓毒症患者细胞免疫的影响。方法50例脓毒症患者随机均分为两组，对照组予常规综合治疗，血必净组加用血必净注射液。两组患者于治疗前和治疗后第3、7d抽取外周血，用流式细胞仪检测CD4＋T细胞、CD8＋T细胞、CD4＋CD25＋T细胞占淋巴细胞的比例及CD14＋单核细胞HLA—DR的表达。结果治疗后两组的CD4＋T细胞占淋巴细胞的比例均显著高于治疗前（均P〈0．01）；而血必净组又显著高于对照组（P〈0．05）。治疗后两组CD8＋T细胞占淋巴细胞的比例均显著低于治疗前（均P〈0．05）；血必净组又显著低于对照组（均P〈0．05）。治疗后第7d，两组外周血CD4＋CD25＋T细胞占淋巴细胞的比例分均显著低于治疗前；而血必净组又显著低于对照组（P〈0．05）。治疗后第7d，两组CD14＋单核细胞HLA—DR表达百分率均显著高于治疗前，血必净又显著高于对照组（均P〈0．05））。结论血必净注射液能纠正脓毒症患者细胞免疫功能紊乱，起到免疫调节功能。

Effect of Xuebijing injection on cyto-immunologic function in patients with sepsis

Objective To investigate the effects of Xuebijing injection on cyto-immunologic function in patients with sepsis. Methods Fifty patients with sepsis were randomly divided into two equal groups to undergo conventional comprehensive treatment （control group） or Xuebijing injection in addition to conventional comprehensive treatment （Xuebijing group）. The changes of the proportions of CD4＋,CD8＋, CD4＋CD25＋ T cells and the expression of CD14＋ monocyte human leukocyte antigen DR of the two groups were detected by flow cytometry respectively before treatment, and on the first, third and seventh days after the initiation of treatment. Results The proportions of CD4＋ T cells of the control and Xuebijing groups on the 7th treatment day were （33.79±15.04）% and （37.90±15.41）% respectively, both significantly higher than those before treatment （27.24±11.94）% and （26.13±11.32）% respectively], and that of the Xuebijing group was significantly higher than that of the control group （all P〈0.05）. The proportions of CD8＋ T cells of the control and Xuebijing groups on the 7th treatment day were （5.78±2.21）% and （4.28±2.34）% respectively, both significantly lower than those before treatment （8.03±3.64）% and （8.11±2.97）% respectively], and that of the Xuebijing group was significantly lower than that of the control group （all P〈 0.05）. The proportions of CD4＋CD25＋ T cells of the control and Xuebijing groups on the 7th treatment day were （5.21±2.34）% and （4.03±2.44）% respectively, both significantly lower than those before treatment （6.13±3.11）% and （6.33 ＋3.67）% respectively], and that of the Xuebijing group was significantly lower than that of the control group （all P〈0.05）. The positive perecentage of CD14＋ monoeyte human leukocyte antigen DR of the control and Xuebijing groups on the 7th treatment day were （20.51±8.97）% and （24.83±9.34）% respectively, both significantly higher than those before treatment （13.67±7.45）% and （12.24±6.95）% respectively], and that of the Xuebijing group was significantly higher than that of the control group （all P〈 0.01）. Conclusion Xuebijing injection can rectify the disorder of cyto-immunologie function in patients with sepsis, thgus regulating the immune functions.